Biotechnology

Tempest Therapeutics

Tempest Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7907 (forecast USD -3.27)

Tempest Therapeutics released FY2025 9 Months Earnings on November 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -6.0193

Tempest Therapeutics released FY2025 Semi-Annual earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -5.1721 (forecast USD -9.62)

Tempest Therapeutics released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.07 (forecast USD -3.23)

Tempest Therapeutics Gains NMPA Approval for Liver Cancer Drug Trial

Tempest Therapeutics Inc. Files $6.25M Direct Offering Prospectus

Tempest Therapeutics Terminates ATM Prospectus Supplement

Tempest Therapeutics' amezalpat granted Orphan Drug Designation by EMA

Tempest Therapeutics Inc Q1 2025 EPS Loss Narrowed

Tempest Therapeutics released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.1591 (forecast USD -3.1525)

Tempest Therapeutics Reports Increased Net Loss in Q1 2025

Tempest Therapeutics Inc reports loss of $3.29 per share

Tempest Therapeutics Discloses New Data on Amezalpat

Tempest Therapeutics' TPST-1495 Receives Orphan Drug Designation from FDA

Scotiabank Downgrades Tempest Therapeutics Rating to Market Perform, Target Price Reduced to $9.00

HC Wainwright & Co. Downgrades Tempest Therapeutics (TPST.US) Rating to Neutral

Tempest Therapeutics Plans to Explore Comprehensive Cancer Treatment Options

Tempest Therapeutics Plans to Explore Strategic Options with MTS Health Partners to Advance Clinical Projects

Tempest Therapeutics Announces Reverse Stock Split

Scotiabank Adjusts Rating and Target Price for Tempest Therapeutics

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap